Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100x
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
CAMBRIDGE, Mass. , March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate...
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
- Connect with the Company on Webull here
JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026
Register for the two-day virtual event here
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
– Live video webcast on Tuesday, February 10 th at 1:20 PM EST
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement
Access the "What This Means" segment here
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP 3 ACT™ platform...